世界のHIVワクチン市場機会及び パイプライン分析...市場調査レポートについてご紹介

1. Introduction to HIV Vaccine & Mechanism
1.1 Introduction
1.2 The Mechanics of HIV Vaccines

2. HIV Vaccine: Prevention & Cure
2.1 Prevention
2.2 Cure & Access to Antiretroviral Therapy

3. Why Need For HIV Vaccines?

4. Global HIV Vaccine Market Outlook
4.1 HIV Incidence Scenario
4.2 Market Overview
4.3 Clinical Trial Analysis

5. Research & Development Funding Scenario for HIV Vaccine

6. HIV Vaccine Market Dynamics
6.1 Favorable Market Drivers
6.2 Challenges to be Resolved
6.3 Future Growth Opportunity

7. FDA Regulatory Framework for Development of HIV Vaccine
7.1 Development of Preventive HIV Vaccines for Use in Paediatric Populations
7.2 Guidance for Submitting HIV Resistance Data
7.3 HIV Resistance Testing in Antiretroviral Drug Development

8. HIV Vaccine Clinical Trial by Phase & Country
8.1 Research
8.2 Preclinical
8.3 Clinical
8.4 Phase I
8.5 Phase I/II
8.6 Phase II
8.7 Phase III

9. Discontinued & Suspended HIV Vaccine Clinical Trial by Phase & Country
9.1 No Development Reported
9.2 Discontinued
9.3 Suspended

10. Competitive Landscape
10.1 Antigen Express
10.2 Bionor Pharma
10.3 FIT Biotech
10.4 GeoVax
10.5 GenVec
10.6 Glaxo Smithkline
10.7 Immune Response BioPharma
10.8 Inovio Pharmaceuticals
10.9 Novartis
10.10 Sanofi Pasteur

List of Figures

Figure 1-1: Vaccine Research Process
Figure 4-1: People Living With HIV Infection (Million), 2009-2014
Figure 4-2: New Incidence of HIV Infection (Million), 2009-2012
Figure 4-3: People Living With HIV Infection by Region (%), 2012
Figure 4-4: People Accessing Treatment for HIV Infection (Million), 2009-2012
Figure 4-5: Global HIV/AIDS Therapeutics Market (US$ Billion), 2012-2018
Figure 4-6: HIV Vaccines in Clinical Trial by Phase (%), 2014
Figure 4-7: Number of HIV Vaccines in Clinical Trial by Phase, 2014
Figure 4-8: Suspended & Discontinued HIV Vaccines in Clinical Trial (%), 2014
Figure 4-9: Number of Suspended & Discontinued HIV Vaccines in Clinical Trial, 2014
Figure 4-10: Discontinued HIV Vaccines in Clinical Trial by Phase (%), 2014
Figure 4-11: Number of Discontinued HIV Vaccines in Clinical Trial by Phase, 2014
Figure 4-12: HIV Vaccines in Clinical Trial by Phase Where No Development Reported (%), 2014
Figure 4-13: Number of HIV Vaccines in Clinical Trial by Phase Where No Development Reported, 2014
Figure 5-1: Global HIV Vaccines R&D Funding (US$ Million), 2005–2012
Figure 5-2: Global HIV Vaccines R&D Funding Breakup (%), 2012
Figure 5-3: Philanthropic Sector Spending on HIV Vaccines by Clinical Research Phase (%),
2012

List of Tables

Table 5-1: HIV Vaccines Funding by Sector (US$ Million), 2006-2012
Table 6-1: HIV Vaccine Impact Analysis on Incidence & Deaths